Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $939,625.74. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00.

United Therapeutics Trading Down 0.8 %

Shares of UTHR stock opened at $361.64 on Thursday. The firm has a fifty day moving average price of $369.86 and a 200 day moving average price of $353.31. The company has a market cap of $16.15 billion, a P/E ratio of 15.88, a PEG ratio of 1.05 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period in the previous year, the company earned $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Choreo LLC purchased a new stake in United Therapeutics in the second quarter valued at $336,000. American Century Companies Inc. lifted its position in United Therapeutics by 42.8% in the second quarter. American Century Companies Inc. now owns 41,233 shares of the biotechnology company’s stock valued at $13,135,000 after acquiring an additional 12,360 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of United Therapeutics by 11.4% in the second quarter. Oppenheimer & Co. Inc. now owns 5,170 shares of the biotechnology company’s stock valued at $1,647,000 after buying an additional 530 shares during the last quarter. Dai ichi Life Insurance Company Ltd raised its holdings in shares of United Therapeutics by 10.5% in the second quarter. Dai ichi Life Insurance Company Ltd now owns 9,202 shares of the biotechnology company’s stock valued at $2,931,000 after buying an additional 873 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of United Therapeutics by 18.2% in the second quarter. Parallel Advisors LLC now owns 937 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 144 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on UTHR. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.